Phase 4
N=70
Single-shot TAP Block vs Continuous TAP Block
Postoperative Pain
Bottom Line
View on ClinicalTrials.gov: NCT02475031 ↗Enrolled (actual)
70
Serious AEs
—
Results posted
May 2017
Primary outcome: Primary: Total Narcotic Usage at 48 Hours — 2.44; 2.88 mg
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- TAP-C (Device); TAP-S (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Indiana University
- Primary completion
- Dec 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Total Narcotic Usage at 48 Hours |
2.44; 2.88 | — |
| SECONDARY Secondary Endpoints Measured Will be Total Narcotic Usage at 60 Hours |
14.31; 14.40 | — |
| SECONDARY Average Pain Scores |
5.31; 5.06 | — |
| SECONDARY Nausea Scores at 48 Hours |
0.34; 0.34 | — |
| SECONDARY Sedation Scores at 48 Hours |
0.2; 0.06 | — |
Summary
The purpose of this study is to determine whether continuous transversus abdominis plane (TAP) block is superior to single shot TAP for postoperative pain after laparoscopic donor nephrectomy
Eligibility Criteria
Inclusion criteria
- Healthy subject undergoing laparoscopic live donor nephrectomy
- (ASA) American Society of Anesthesiologists class 1 or 2
- Age 18 or older, male or female
- Desires TAP block for postoperative pain control
Exclusion criteria
- Any contraindication for TAP block - single or continuous
- History of substance abuse
- Any physical, mental or medical conditions which, in the opinion of the investigators, may confound quantifying postoperative pain resulting from surgery.
- Known allergy or other contraindications to the study medications (Ropivacaine, Normal Saline, Hydromorphone, Oxycodone and Acetaminophen)
Data sourced from ClinicalTrials.gov (NCT02475031). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.